Arrowhead Pharmaceuticals Begins Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease and Tauopathies
Novel RNAi Therapy Uses Subcutaneous Delivery to Cross the Blood-Brain Barrier Company:Arrowhead Pharmaceuticals has announced the initiation of a Phase […]